Alkermes plc (ALKS) Earnings Call Transcripts

Alkermes plc's Latest Earnings Call - June 10, 2026

In the earnings call held on June 10, 2026, Alkermes plc (ALKS:US) highlighted significant advancements in their pipeline, particularly with the rexinagonist program, which is now enrolling in Phase III trials after a successful Phase II. The company reported a robust $1.7 billion top-line commercial business that supports ongoing innovation. Management expressed confidence in their strategic direction, emphasizing that execution will drive valuation expansion. No specific revenue or earnings figures were disclosed during the call, and guidance for the upcoming quarters remains unchanged.

Reported metrics

Guidance from management

Management maintained guidance for continued execution in their pipeline and commercial business, emphasizing the importance of strategic flexibility and innovation.

What management said

Yes. I think if you look over the last year, we've really been looking to widen our portfolio and our pipeline in our agonism. And really laying down a number of different bets over the next little while and programs that are going to report out over the next 12 months. So we're in a really exciting moment for the company and a moment of really execution and change. And so I think everybody in the company is really...

What's interesting, we have a $1.7 billion top line commercial business that drives tremendous profitability and a lot of cash flow, and most people don't care at all about it. But we care a lot about it because it's the flywheel that powers all this innovation that we've been able to do in a nondilutive way for our shareholders. We bought Avadel, which brought us into the hypersonics business from a commercial persp...

What analysts pressed on

Analysts expressed concerns regarding the competitive landscape for rexinagonists and the potential impact of new entrants on market share. There were questions about the robustness of clinical data and the ability to maintain differentiation in a crowded market.

Main topics on the call

• Rexinagonist Program Progress — Alkermes is advancing its rexinagonist program, which is now enrolling in Phase III trials following a strong Phase II performance. Richard Pops stated, "we think this is a really exciting opportunity" and emphasized the...
• Acquisition of Avadel — The acquisition of Avadel is seen as a strategic move to bolster Alkermes' commercial capabilities and expand into the hypersonics business. Blair Jackson noted that the integration has been smooth, stating, "we hit the ...
• CEO Transition — Richard Pops announced his transition to Chairman, with Blair Jackson taking over as CEO. Pops expressed pride in the company's impact on patient lives, stating, "over 200,000 patients will get Alkermes medicines this ye...
• Pipeline Expansion — Management indicated a focus on expanding the pipeline with new programs targeting ADHD and fatigue, with Blair Jackson mentioning, "we're in a really exciting moment for the company" as they prepare for upcoming data re...

Read the full Alkermes plc transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 70 Alkermes plc earnings call transcripts on record, spanning January 15, 2020 to July 28, 2026. Based on this history, Alkermes plc reports quarterly. The most recent call on file is dated July 28, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ALKS

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

70

First call

January 15, 2020

Most recent

July 28, 2026

Reporting cadence

quarterly